NCT07409272 2026-04-16
A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer
Astellas Pharma Inc
Phase 3 Recruiting
Clinical Trials
11 trialsNCT06958328 2026-04-08
LAP100
NRG Oncology
Phase 3 Recruiting
NCT06998940 2026-03-27
Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations
SWOG Cancer Research Network
Phase 3 Recruiting
NCT04340141 2026-02-10
Testing the Use of the Usual Chemotherapy Before and After Surgery for Removable Pancreatic Cancer
Alliance for Clinical Trials in Oncology
Phase 3 Active not recruiting
NCT06625320 2025-12-12
RASolute 302
Revolution Medicines, Inc.
Phase 3 Active not recruiting
NCT06897644 2025-05-25
PANThEON
Gruppo Oncologico del Nord-Ovest
Phase 3 Recruiting
NCT03750669 2025-05-13
Sequential Use of AG and mFOLFIRINOX as Neoadjuvant Chemotherapy for Resectable Pancreatic Cancer
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 3 Completed
NCT04927780 2024-08-28
PREOPANC-3
Erasmus Medical Center
Phase 3 Recruiting
NCT02539537 2024-01-09
NEOPAN
UNICANCER
Phase 3 Completed
NCT01926197 2022-10-28
Phase 3 Study of FOLFIRINOX (mFFX) +/- SBRT in Locally Advanced Pancreatic Cancer
Stanford University
Phase 3 Completed
NCT01836432 2020-05-28
PILLAR
Lumos Pharma
Phase 3 Terminated